Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. The agency is now heavily scrutinizing Phase 1 and 2 studies to see whether they identify the safest and most effective dose—while this change seems abrupt, it’s loomed over the field for a long time.
We’ve helped our clients adapt to the new standards with five best practices outlined in this article.
Related Insights
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
Regulatory considerations in designing clinical trials for Alzheimer’s disease
Jan 24, 2024
Related Insights
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
Regulatory considerations in designing clinical trials for Alzheimer’s disease
Jan 24, 2024